1 / 7

Pricing: Observations

Pricing: Observations. Nazeem Mohamed Chairman, Uganda Pharmaceutical Manufacturers Association (UPMA) C.E.O. Kampala Pharmaceutical Industries (1996) Ltd. Pricing: Information/Data Gathering. Robust methodologies and publications exist (WHO/HAI) on pricing of medicines

kimberly
Télécharger la présentation

Pricing: Observations

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pricing: Observations Nazeem Mohamed Chairman, Uganda Pharmaceutical Manufacturers Association (UPMA) C.E.O. Kampala Pharmaceutical Industries (1996) Ltd

  2. Pricing: Information/Data Gathering Robust methodologies and publications exist (WHO/HAI) on pricing of medicines Share data across countries on “public procurement” as means to increase efficiency Data must be shared across multi-sectors before policies are finalised – Transparency is the key!! Pricing/Affordability must go hand in hand Convert prices into a Availability Index (no’s days wages to pay for treatment) A finding may have many causes!! Information must be dynamic and communicated!!!

  3. Pricing: Policy • Pricing is only one aspect of the “access” issue and there is NO one answer!! • Effective policy will have to be a package of measures addressing pricing, e.g. • Generic substitution • Price/margin controls • Procurement efficiency • Differential pricing • Support local manufacturing • Increase public sector availability • Need for a financing mechanism for the poor and even the near poor • Must measure the impact of policy and be prepared to adjust as necessary

  4. Pricing: Issues • Watch for unwanted negative effects • Price controls may impact on availability • Growth of cheaper sub standard products • Asymmetric information, i.e. Choice of medicine not made by the end consumer!! • Consider the impact of “Chronic diseases” when developing policy (priorities!) • Health system strengthening • Financing options

  5. Pricing: MeTA Country Achievements

  6. Pricing: MeTA Country Achievements

  7. Thank you Nazeem Mohamed Email: nazeem@kpi.co.ug

More Related